Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Director departure
CC transcript

AGENUS INC (AGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 4 ARMEN GARO H (See Remarks) has filed a Form 4 on AGENUS INC
Txns: Granted 15,305 shares @ $1.06, valued at $16.2k
10/06/2023 4 AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.
Txns: Bought 15,001 shares @ $1.0919, valued at $16.4k
10/04/2023 4 Wright Timothy (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 6,586 restricted stock units @ $0
10/04/2023 4 Hirsch Susan B (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 14,928 restricted stock units @ $0
10/04/2023 4 WIINBERG ULF (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 18,001 restricted stock units @ $0
08/23/2023 8-K Cost Associated with Exit or Disposal Activities, Financial Statements and Exhibits  Interactive Data
Docs: "Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Agenus Reports Second Quarter 2023 Results"
07/06/2023 4 Hirsch Susan B (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 13,283 restricted stock units @ $0
07/06/2023 4 WIINBERG ULF (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 16,018 restricted stock units @ $0
07/06/2023 4 Wright Timothy (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 5,860 restricted stock units @ $0
05/26/2023 4/A AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.
05/26/2023 4/A AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.
Txns: Disposed of 5,006,397 shares @ $0
05/26/2023 SC 13D/A AGENUS INC reports a 62.5% stake in MINK THERAPEUTICS, INC.
05/12/2023 4 AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.
Txns: Bought 22,065 shares @ $1.509, valued at $33.3k
Bought 23,361 shares @ $1.4275, valued at $33.3k
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Agenus Provides Corporate Update and First Quarter 2023 Financial Results"
05/05/2023 4 AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.
Txns: Bought 128,689 shares @ $1.0789, valued at $138.8k
Bought 21,473 shares @ $1.2223, valued at $26.2k
Bought 100,000 shares @ $0.9485, valued at $94.9k
Bought 200 shares @ $1.25, valued at $250
05/03/2023 4 AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.
Txns: Disposed of 4,988,273 shares @ $0
05/03/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/24/2023 8-K Quarterly results
04/03/2023 4 Hirsch Susan B (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 9,870 restricted stock units @ $0
04/03/2023 4 WIINBERG ULF (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 11,902 restricted stock units @ $0
04/03/2023 4 Wright Timothy (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 4,354 restricted stock units @ $0
03/30/2023 8-K Quarterly results
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/14/2023 8-K Quarterly results
Docs: "Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer , 50% in PD-1 refractory non-small cell lung cancer and in seven additional metastatic, late-line cancers in a total of more than 300 patients Randomized Phase 2 trials in MSS CRC, melanoma, and pancreatic cancers are underway; a confirmatory phase 3 trial in MSS CRC is expected to be launched in 2023 Data demonstrating clinical benefit in MSS CRC, NSCLC, ovarian cancer, and sarcomas were presented in plenary sessions at ESMO GI, SITC, and CTOS in 2022, and in a late-breaking oral session at ASCO GI in January 2023 Existing corporate collaborations have potential to generate up to $2.7B ..."
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8% stake in Agenus Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/09/2023 4 Hirsch Susan B (Director) has filed a Form 4 on AGENUS INC
Txns: Granted 100,000 options @ $2.4, valued at $240k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy